UB-311

BIOLOGICAL2 trials

Sponsors

United Neuroscience Ltd.

Conditions

Alzheimer's Disease

Phase 2

Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients

CompletedNCT02551809

United Neuroscience Ltd.Alzheimer's Disease

Start: 2015-10-31End: 2018-08-31Updated: 2020-03-17

An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311

TerminatedNCT03531710

United Neuroscience Ltd.Alzheimer's Disease

Start: 2018-08-10End: 2019-10-31Updated: 2021-01-26

Related Papers

Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study.

2023-06-2927 citations

UB‐311, a novel UBITh <sup>®</sup> amyloid β peptide vaccine for mild Alzheimer's disease

Alzheimer s & Dementia Translational Research & Clinical Interventions2017-04-14139 citations